Annual Drug Patent Expirations for TRELEGY+ELLIPTA
Trelegy Ellipta is a drug marketed by Glaxosmithkline and is included in one NDA. It is available from one supplier. There are fourteen patents protecting this drug.
TRELEGY ELLIPTA drug price trends.
Drug patent litigation for TRELEGY ELLIPTA.
This drug has one hundred and fifty-nine patent family members in forty-eight countries.
The generic ingredient in TRELEGY ELLIPTA is fluticasone furoate; umeclidinium bromide; vilanterol trifenatate. One supplier is listed for this compound. Additional details are available on the fluticasone furoate; umeclidinium bromide; vilanterol trifenatate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
